Introduction {#s0005}
============

Colorectal cancer (CRC) is a major cause of morbidity and mortality worldwide. The incidence of CRC in Korea has increased dramatically over the past few decades; however, the incidence rates of other more common cancers, such as stomach and liver cancers, have decreased [@bb0005]. Recently, molecularly targeted drugs, such as cetuximab (Erbitux®; Merck KGaA, Darmstadt, Germany), an epidermal growth factor receptor (EGFR)-targeted monoclonal antibody, and the vascular endothelial growth factor (VEGF)-targeted monoclonal antibody bevacizumab (Avastin®; Genentech Inc., CA, U.S.) [@bb0010], [@bb0015], [@bb0020], have been developed to treat metastatic CRC. However, serious limitations are associated with the use of these targeted drugs, and it is thus necessary to develop prognostic biomarkers and novel therapeutic targets based on the molecular mechanisms underlying CRC pathogenesis. Recently, due to the development of next generation sequencing (NGS) technology, several studies have revealed candidate therapeutic targets for treating colon cancer, including fusion genes and oncogenic driver mutations [@bb0025], [@bb0030]. Among these, gene fusions with neurotrophic tyrosine kinase receptor 1 (*NTRK1*), such as *TPM3-NTRK1* and *LMNA-NTRK1*, have been reported in CRC [@bb0035], [@bb0040], [@bb0045], [@bb0050]. *NTRK1* encodes the TrkA receptor, which is a member of the Trk (tropomyosin receptor kinase) family of receptor tyrosine kinases (RTKs) [@bb0055]. *NTRK1* activation induces the PI3K/AKT, Ras/MAPK, and PLC-gamma signaling pathways [@bb0060]. *NTRK1* gene fusions are therapeutic targets for multikinase inhibitors, such TrkA inhibitors.

Although the optimal method for detecting NTRK1 gene fusions has not yet been determined, three methods, DNA-based NGS assays, targeted panels using RNA, and fluorescence in situ hybridization (FISH) are widely used [@bb0065]. DNA-based NGS methods can fail to detect fusion genes due to the analysis of introns (size limitation) and problems with the degradation of using formalin-fixed paraffin embedded tissue (FFPE) specimens. Targeted RNA methods have similar sample quality problems (RNA quality in FFPE tissues). The FISH method has an advantage as it can detect fusions genes in FFPE specimens and has been used in lung cancer [@bb0070]; however, the results cannot be used to identify the fusion partner or differences between fusion variants. These methods are time consuming, expensive and have issues with specimen quality. Recently, immunohistochemical (IHC) analysis using an antibody targeted against the C-terminal intracellular domain of TrkA was reported for detecting *NTRK1* gene fusions [@bb0040], [@bb0060]. However, standardization of IHC results for determining TrkA protein expression, similar to the standardization of ALK expression for detecting *ALK* fusion genes in lung cancer [@bb0075], has not been reported. Thus, we validated IHC TrkA expression as a screening method for detecting *NTRK1* fusions in 80 CRC tissue samples.

Materials and Methods {#s0010}
=====================

Commercially available split FISH probes were used for detecting the *NTRK1* gene fusions in CRC tissues according to the manufacturer\'s instructions (FS0024; Abnova, Taipei City, Taiwan). The study included a cohort of 80 patients with T3 or T4 CRC, who underwent resection of the primary tumor at Pusan National University Hospital (PNUH) between January and May 2015. The group consisted of 44 men and 36 women, with a mean age of 67.8 years (range, 31-87 years). Standard FFPE sections were obtained from the Department of Pathology and the National Biobank of Korea, Pusan National University Hospital. All samples from the National Biobank of Korea were procured after obtaining informed consent of the patients and were subjected to institutional review board-approved protocols. Briefly, TrkA expression was confirmed in deparaffinized, protease-treated FFPE tissue sections using an anti-TrkA C-terminal monoclonal antibody (TA806413; OriGene, Rockville, MD, U.S.). Brain ganglions and lymphocytes served as positive and negative controls, respectively. TrkA immunostaining was observed to be both membranous and cytoplasmic ([Figure 1](#f0005){ref-type="fig"}) and was semiquantitatively scored \[staining intensity: negative (0), weak (1), moderate (2), strong (3); staining percentage: 0%-5% (0), 5%-25% (1), 25%-50% (2), ≥50% (3)\]. For interpretation of TrkA cytoplasmic and membranous staining, each pathologist (SJL, AK, and DYP) first separately scored and in cases with differing results, samples were reviewed again using a multi-viewer microscope. Simultaneously, deparaffinized and protease-treated FFPE tissue sections were denatured at 75 °C and incubated overnight with 5′-end TexRed-labeled and 3′-end FITC-labeled probes for *NTRK1*. After washing and DAPI counterstaining (32--804,831; Abbott, Chicago, IL, U.S.), the number and localization of hybridization signals were assessed. Tumors were determined to be *NTRK1* gene fusion positive when more than 20 out of 100 nuclei demonstrated break-apart 5′- and 3′-end signals ([Figure 2](#f0010){ref-type="fig"}). The relationship between the *NTRK1* FISH-positive and TrkA IHC-positive results was assessed using the Spearman\'s rank correlation coefficient. The ability of TrkA IHC to predict the detection of *NTRK1* gene fusions by FISH was assessed using ROC curve analysis. Clinicopathological features were analyzed for the *NTRK1* gene fusions using the Student\'s *t*-test, χ^2^ test, or Fisher\'s exact test. The results were considered to be statistically significant at *P* \< .05. Statistical analysis was performed using SSPS version 10.0 for Windows (SPSS Inc., Chicago, IL, USA).Figure 1IHC staining patterns of TrkA in CRC tissue samples. (A) Cytoplasmic, (B) membranous, and (C) mixed cytoplasmic and membranous staining patterns are shown.Figure 1Figure 2FISH assay using split FISH probes for confirming *NTRK1* rearrangements. Split red and green signals were observed (yellow arrows), which indicated *NTRK1* gene fusions. The scale bar indicates 20 μm.Figure 2

Results {#s0015}
=======

We detected the expression of *NTRK1* gene fusions and TrkA and determined the relationship between FISH and IHC results for *NTRK1* gene fusion analysis. We simultaneously performed FISH using split FISH probes and IHC using an anti-TrkA C-terminal monoclonal antibody using FFPE sections obtained from 80 CRC patients. The IHC analysis of TrkA in CRC tissue samples revealed two staining patterns (cytoplasmic and membranous). About 80% of the CRC samples (64/80) showed both cytoplasmic and membranous staining. Additionally, heterogeneous cytoplasmic or membranous staining in the CRC tissue sections was observed. [Figure 3](#f0015){ref-type="fig"} shows heterogeneous cytoplasmic staining of adenocarcinoma tissue, which coincides with FISH-positive *NTRK1* gene fusion sites and increased cytoplasmic staining of TrkA.Figure 3Cytoplasmic TrkA immunostaining showing (A) negative, (B) weak, (C) moderate, and (D) strong staining intensities. Membranous TrkA immunostaining showing (E) negative, (F) weak, (G) moderate, and (H) strong staining intensities.Figure 3

For the IHC analysis using an anti-TrkA C-terminal monoclonal antibody, we independently evaluated and scored cytoplasmic and membranous TrkA expression. For the intensity scoring of cytoplasmic TrkA expression, negative (0), weak (1), moderate (2), and strong (3) cytoplasmic TrkA expression was noted in 20.0% (16/80), 26.3% (21/80), 38.8% (31/80), and 15.0% (12/80) of samples, respectively. With regard to the proportional scoring of cytoplasmic TrkA expression, 0%-5% (0), 5%-25% (1), 25%-50% (2), and ≥50% (3) cytoplasmic TrkA expression was identified in 21.3% (17/80), 21.3% (17/80), 36.3% (29/80), and 21.3% (17/80) of the samples, respectively. For the intensity scoring of membranous TrkA expression, negative (0), weak (1), moderate (2), and strong (3) membranous TrkA expression was noted in 6.3% (5/80), 40.0% (32/80), 50.0% (40/80), and 3.8% (3/80) of samples, respectively. With regard to the proportional scoring of membranous TrkA expression, 0%-5% (0), 5%-25% (1), 25%-50% (2), and ≥50% (3) membranous TrkA expression was identified in 6.3% (5/80), 11.3% (9/80), 38.8% (31/80), and 43.8% (35/80) of samples, respectively ([Figure 3](#f0015){ref-type="fig"}). The *NTRK1* gene fusion analysis using FISH indicated *NTRK1* gene fusions were present in 7.5% (6/80) of the samples. Comparing the results of the two assays for each sample, we observed heterogeneous TrkA immunostaining was associated with either strong cytoplasmic TrkA expression and frequent *NTRK1* rearrangements or weak to moderate cytoplasmic TrkA expression and less frequent *NTRK1* rearrangements ([Figure 4](#f0020){ref-type="fig"}).Figure 4Heterogeneous TrkA immunostaining in the CRC tissues analyzed using FISH. (A & B) Strong cytoplasmic TrkA expression in adenocarcinoma tissues showing frequent *NTRK1* rearrangements. (C & D) Weak to moderate cytoplasmic TrkA expression in adenocarcinoma tissues revealing less frequent *NTRK1* rearrangements. Split red and green signals (yellow arrows) indicate *NTRK1* fusion genes. The scale bar indicates 20 μm.Figure 4

A significant correlation between the FISH and IHC results for *NTRK1* gene fusion analysis was seen. We observed cytoplasmic TrkA expression with the area under the receiver operating characteristic (ROC) curve as 0.926 (0.864-0.987, 95% CI, *P* = .001) ([Figure 5](#f0025){ref-type="fig"}). By choosing 4.5 (the sum of the cytoplasmic TrkA expression scores) as the cut-off value for the *NTRK1* gene fusion positive and negative groups, the sensitivity and specificity of predictions of lymph node metastasis were 100 and 83.8%, respectively (*P* = .001). Specifically, high (or strong) cytoplasmic TrkA expression (sum of the intensity and proportion score \> 4) was associated with the detection of *NTRK1* gene fusions (*P* \< .0001, r = 0.528) ([Table 1](#t0005){ref-type="table"}). In order to assess the characteristics of the *NTRK1* gene fusion-positive CRC samples, we analyzed various clinicopathological features in all 80 CRC patients. We observed that the *NTRK1* gene fusion-positive tumors were associated with younger patients (*P* = .051). Other clinicopathological features including sex, tumor location, histological differentiation, perineural invasion, invasion depth, lymphovascular invasion, lymph node metastasis, and microsatellite instability status were not associated with the detection of *NTRK1* gene fusions ([Table 2](#t0010){ref-type="table"}).Figure 5ROC curve analysis for TrkA immunostaining to predict *NTRK1* gene fusions using FISH. Cytoplasmic TrkA expression, yielding an area under the ROC curve of 0.926 (range: 0.864--0.987, 95% CI, *P* = .001) is shown.Figure 5Table 1Relationship Between FISH and IHC for *NTRK* Fusion Gene Analysis in CRC PatientsTable 1Sum of Intensity and Proportion Score\[No.\]FISH for NTRK Fusion Gene*P*NegativePositiveIHC cytoplasmic 0--46262 (100.0)0 (0.0)\<.0001 5--61812 (66.7)6 (33.3)IHC membranous 0--45451 (94.4)3 (5.6).384 5--62623 (88.5)3 (11.5)Table 2Relationship Between *NTRK1* Fusion Gene Revealed by FISH Analysis and Clinicopathological Characteristics in 80 Patients With Colorectal CancerTable 2\[No.\]FISH for NTRK Fusion Gene*P*NegativePositiveAge (years)8068.5 ± 1.2359.5 ± 4.65.051Size (cm)805.72 ± 0.245.40 ± 1.13.720Sex Male4441 (93.2)3 (6.8)1.000 Female3633 (91.7)3 (8.3)Location Right colon2221 (95.5)1 (4.5)1.000 Left colon5853 (91.4)5 (8.6)Histological type\*.582 Well22 (100.0)0 (0.0) Moderately6559 (90.8)6 (9.2) Poorly1010 (100.0)0 (0.0) Mucinous33 (100.0)0 (0.0)Invasion depth.328 T35656 (90.3)6 (9.7) T41818 (100.0)0 (0.0)Perineural invasion1.000 Negative4037 (92.5)3 (7.5) Positive4037 (92.5)3 (7.5)Lymphatic emboli.079 Negative5044 (88.0)6 (12.0) Positive3030 (100.0)0 (0.0)Venous emboli Negative7064 (91.4)6 (8.6)1.000 Positive1010(100.0)0 (0.0)Lymph node\
metastasis.676 Negative3933 (94.9)2 (5.1) Positive4136 (90.2)4 (9.8)Microsatellite status.480 MSS7065 (92.9)5 (7.1) MSI-L22 (100.0)0 (0.0) MSI-H87 (87.5)1 (12.5)

Discussion {#s0020}
==========

With the recent development of multi-omics data analysis tools and sequencing methods, several studies have revealed novel therapeutic targets such as gene fusions (e.g., the *NTRK1* and *RSOP* gene fusion in CRC) [@bb0025], [@bb0030]. Among these, the *NTRK1* gene fusions, such as *TPM3-NTRK1* and *LMNA-NTRK1*, have been reported in CRC patients [@bb0035], [@bb0040], [@bb0045], [@bb0050]. *NTRK1* gene fusions are therapeutic targets for multikinase inhibitors, such TrkA inhibitors. *NTRK1* encodes the TrkA receptor, which is a member of the Trk family of RTKs. Its activation induces the PI3K/AKT, Ras/MAPK, and PLC-gamma signaling pathways [@bb0055], [@bb0060]. The dysregulation of the kinase activity of Trk is associated with carcinogenesis.

We identified *NTRK1* gene fusions in 7.5% (6/80) of CRC samples using FISH. This incidence rate is higher than that reported by previous studies \[2.7% (2/74, using NGS), 1.7% (1/66, using qRT-PCR), 2% (3/147, using RNA sequencing), and 0.5% (2/408, using IHC and qRT-PCR)\] [@bb0035], [@bb0040], [@bb0045], [@bb0050]. We believe that these discrepancies can be partly attributed to the differences in detection methods or study cohorts. Unlike other studies, we simultaneously performed FISH and IHC, using split FISH probes using an anti-TrkA monoclonal antibody, in FFPE sections obtained from 80 CRC patients. Lee et al. performed IHC for TrkA and confirmed *NTRK1* gene fusions using NGS [@bb0045]. Ardini et al. used qRT-PCR to detect the high expression level of mRNA coding for the intracellular domains of *NTRK1* and confirmed these results using PCR and direct DNA sequencing [@bb0035]. Park et al. initially performed RNA-sequencing analysis and then confirmed *NTRK1* gene fusions using FISH [@bb0050]. Créancier et al. used IHC and qRT-PCR to detect *NTRK1* gene fusions in CRC samples [@bb0040]. However, these methods could potentially yield false-negative and false-positive results. Although testing of fusion genes was based on FISH in many laboratories, FISH and other molecular methods have various limitations (cost, turn-around time, and FFPE specimen quality problems). Conklin et al. reported that IHC was a reliable method to detect *ALK* rearrangements identified by FISH in non-small cell lung cancer [@bb0070], and our previous data and studies have shown that strong cytoplasmic TrkA expression was associated with *NTRK1* gene fusions [@bb0035], [@bb0040], [@bb0045], [@bb0050]. Based on these data and findings, we performed a correlation analysis between the results of IHC for TrkA and FISH and analyzed the ability of this screening method to detect *NTRK1* gene fusions in CRC samples, similar to the use of ALK IHC for detecting *ALK* fusion genes in non-small cell lung cancer.

In this study, we used an anti-TrkA monoclonal antibody that recognizes the C-terminal intracellular domain of TrkA as readout for *NTRK1* rearrangements in CRC. However, there have been no previous studies on using the intensity and proportion of cytoplasmic TrkA staining as a predictive marker for *NTRK1* gene fusions. Ardini et al. and Créancier et al. reported only strong cytoplasmic TrkA staining [@bb0035], [@bb0040]. Lee et al. and Park et al. also reported only cytoplasmic TrkA staining [@bb0045], [@bb0050]. Furthermore, the positive rate for cytoplasmic TrkA staining differed between the different studies (0.5--5.1%) [@bb0035], [@bb0040], [@bb0045], [@bb0050]. Our data revealed a higher frequency of strong cytoplasmic TrkA staining rate (15%, 12/80) compared to the previous studies. We believe that these discrepancies may be partly attributed to the differences in the types of primary antibodies or specimens used. Two studies used a rabbit anti-TrkA monoclonal antibody (ab76291; Abcam, Cambridge, U.K.) [@bb0035], [@bb0040]. Lee et al. used an anti-panTrk rabbit antibody (C17F1; Cell Signaling Technology). Park et al. and the present study used an anti-TrkA C-terminal monoclonal antibody (TA806413; OriGene, Rockville, MD, U.S.). Additionally, three of the studies [@bb0035], [@bb0040], [@bb0050] used tissue microarray technology, and one study used tissue blocks for performing TrkA IHC. As shown above, TrkA expression was observed to be heterogeneous. This may have been partly responsible for the high percentage of strong cytoplasmic TrkA expression observed in our study. Furthermore, for practical purposes, a false negative TrkA IHC results will be of concern due to the heterogeneous expression TrkA expression and *NTRK1* fusion genes. To overcome this issue, we needed to standardize the TrkA IHC method (primary antibodies, dilution and staining platform of immunohistochemistry) and size of specimen (size of tissue). Hechtman et al. reported that specific staining patterns for Trk expression were related with the subcellular localization of the fusion partners [@bb0065]. For example, in case of the *NTRK1-LMNA* fusion, immunostaining was observed in the nuclear membrane; however, in case of the *NTRK1-TPM* fusion, mixed cytoplasmic and membranous staining was observed [@bb0065]. In the present study, all *NTRK1* gene fusion-positive CRC samples displayed mixed cytoplasmic and membranous staining patterns for TrkA. Despite the limitations of our present study (small sample size procured from a single institution), we identified that strong cytoplasmic TrkA expression was associated with the presence of *NTRK1* gene fusions. Additionally, IHC for TrkA can be used as an effective screening method for detecting *NTRK1* gene fusions in CRC. Further multi-institutional studies encompassing larger cohorts, with other IHC methods and primary antibodies, are needed to confirm our present findings.
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